Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes

被引:84
|
作者
Dupuy, C
Buzoni-Gatel, D
Touzé, A
Bout, D
Coursaget, P
机构
[1] Fac Pharm, Mol Virol Lab, F-37200 Tours, France
[2] Fac Pharm, Lab Associe INRA Immunol Parasitaire, EA2637 Proc Infect & Tumoraux, F-37200 Tours, France
关键词
D O I
10.1128/JVI.73.11.9063-9071.1999
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Human papillomavirus type 16 (HPV-16) infects the genital tract and is closely associated with the development of cervical cancer. HPV-16 initiates infection at the genital mucosal surface; thus, mucosal immune responses are likely to contribute to defense against HPV-16 infection. However, little information is available regarding the induction of immune responses in the genital tract mucosa. In this study, we evaluated the potential of intranasally administered papillomavirus vaccines to elicit both systemic and vaginal immune responses. HPV-16 virus-like particles (VLPs) produced by self-assembly of L1 protein and the HPV-16 L1 gene cloned into a mammalian expression vector were used as vaccines. Intranasally administered VLPs induced serum immunoglobulin G (IgG) and vaginal IgA secretory antibodies. Very weak serum IgG and vaginal IgA responses were found after DNA immunization. Both splenic and vaginal lymphocytes could be activated by intranasal immunization with VLPs and the HPV-16 L1 gene. Activated CD4(+) Th1-like T cells were shown to synthesize gamma interferon, and activated CD8(+) T cells were demonstrated to be cytotoxic.
引用
收藏
页码:9063 / 9071
页数:9
相关论文
共 50 条
  • [41] Human Papillomavirus Type 16 (HPV16) E6/E7-Specific Cytotoxic T Lymphocytes (CTLs) for Immunotherapy of HPV-Associated Malignancies
    Ramos, Carlos A.
    Narala, Neeharika
    Leen, Ann M.
    Gerdemann, Ulrike
    Anderson, Matthew L.
    Sturgis, Erich M.
    Savoldo, Barbara
    Heslop, Helen E.
    Brenner, Malcolm K.
    Rooney, Cliona M.
    BLOOD, 2011, 118 (21) : 834 - 835
  • [42] Study of cell-mediated response in mice by HPV16 l1 virus-like particles expressed in Saccharomyces cerevisiae
    Woo, Mi-Kyung
    Hur, Sook-Jin
    Park, Suenie
    Kim, Hong-Jin
    JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, 2007, 17 (10) : 1738 - 1741
  • [43] A recombinant human papillomavirus (HPV) type 16 L1-vaccinia virus murine challenge model demonstrates cell-mediated immunity against HPV virus-like particles
    Marais, D
    Passmore, JA
    Maclean, J
    Rose, R
    Williamson, AL
    JOURNAL OF GENERAL VIROLOGY, 1999, 80 : 2471 - 2475
  • [44] Effect of HPV16 L1 virus-like particles on the aggregation of non-functionalized gold nanoparticles
    Palomino-Vizcaino, Giovanni
    Valencia Resendiz, Diana Gabriela
    Luisa Benitez-Hess, Maria
    Martinez-Acuna, Natalia
    Virginia Tapia-Vieyra, Juana
    Bahena, Daniel
    Diaz-Sanchez, Mauricio
    Patricio Garcia-Gonzalez, Octavio
    Arizai Alvarez-Sandoval, Brenda
    Marat Alvarez-Salas, Luis
    BIOSENSORS & BIOELECTRONICS, 2018, 100 : 176 - 183
  • [45] Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine
    Brown, DR
    Fife, KH
    Wheeler, CM
    Koutsky, LA
    Lupinacci, LM
    Railkar, R
    Suhr, G
    Barr, E
    Dicello, A
    Li, WL
    Smith, JF
    Tadesse, A
    Jansen, KU
    VACCINE, 2004, 22 (21-22) : 2936 - 2942
  • [46] Interleukin/chitosan (JY) adjuvant enhances the mucosal immunity of human papillomavirus 16 L1 virus-like particles in mice
    Fenlian Ma
    Qian Zhang
    Lishu Zheng
    Biotechnology Letters, 2015, 37 : 773 - 777
  • [47] Interleukin/chitosan (JY) adjuvant enhances the mucosal immunity of human papillomavirus 16 L1 virus-like particles in mice
    Ma, Fenlian
    Zhang, Qian
    Zheng, Lishu
    BIOTECHNOLOGY LETTERS, 2015, 37 (04) : 773 - 777
  • [48] Induction of HPV16 capsid protein-specific human T cell responses by virus-like particles
    Rudolf, MP
    Nieland, JD
    DaSilva, DM
    Velders, MP
    Müller, M
    Greenstone, HL
    Schiller, JT
    Kast, WM
    BIOLOGICAL CHEMISTRY, 1999, 380 (03) : 335 - 340
  • [49] Human papillomavirus type 16 (HPV16) E6/E7-specific cytotoxic T lymphocytes (CTL) for immunotherapy of HPV-associated cancer (Ca).
    Ramos, Carlos Almeida
    Narala, Neeharika
    Leen, Ann M.
    Gerdemann, Ulrike
    Sturgis, Erich M.
    Anderson, Matthew L.
    Savoldo, Barbara
    Heslop, Helen E.
    Brenner, Malcolm K.
    Rooney, Cliona M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Antibodies to human papillomavirus 16 L1 virus-like particles as an independent prognostic marker in cervical cancer
    Heim, K
    Widschwendter, A
    Pirschner, G
    Wieland, U
    Awerkiew, S
    Christensen, ND
    Bergant, A
    Marth, C
    Höpfl, R
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2002, 186 (04) : 705 - 711